In the rush to stake a claim in next-generation mental health treatments, biotech headlines are dominated by billion-dollar acquisitions and bold clinical projections. But in the fine print—in courtrooms, patent filings, and regulatory footnotes—a quieter battle is unfolding. And it’s one that could have just as much bearing on who owns the future of psychedelic-inspired therapeutics.
